See analyst estimates and all valuation multiples for Regenerative Medicine
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $112B | 9.3x | 20.7x | |
| $10.1B | 3.2x | 13.6x | |
| $7.2B | 18.5x | 42.7x | |
| $5.4B | 1561.2x | -325.3x | |
| $4.7B | 7.4x | 43.9x | |
| $2.9B | 365.2x | -5.2x | |
| $2.1B | 5.5x | 12.5x | |
| $2.0B | 28.8x | -62.2x | |
| $1.8B | 6.5x | 25.5x | |
| $1.8B | 8.0x | 63.7x | |
| $1.8B | 47.3x | -3.7x | |
| $1.5B | n/a | n/a | |
| $1.3B | 1924.8x | -12.2x | |
| $1.0B | 17.8x | -2.3x | |
| $970M | 61.5x | -5.6x | |
| $925M | n/a | -35.8x | |
| $642M | 1.6x | 6.3x | |
| $586M | 1.1x | 10.1x | |
| $535M | n/a | n/a | |
| $411M | 12.7x | n/a | |
| $409M | 364.0x | n/a | |
| $379M | n/a | -1.0x | |
| $354M | 35.7x | -9.8x | |
| $250M | 20.1x | -72.4x | |
| $225M | 11.6x | n/a | |
| $192M | 70.3x | n/a | |
| $153M | 5.6x | 16.8x | |
| $151M | 18.7x | -26.0x | |
| $145M | 2.5x | 38.6x | |
| $143M | n/a | -0.7x | |
| $117M | 1.1x | 72.3x | |
| $104M | n/a | n/a | |
| $89.9M | n/a | n/a | |
| $80.8M | n/a | n/a | |
| $66.8M | 3.6x | -7.5x | |
| $60.7M | n/a | -4.9x | |
| $60.1M | 641.4x | n/a | |
| $53.3M | n/a | n/a | |
| $53.0M | 16.9x | -7.8x | |
| $29.8M | n/a | n/a | |
| $19.3M | n/a | n/a | |
| $13.7M | 0.7x | n/a | |
| $4.6M | 1.0x | n/a | |
| $2.8M | 2.9x | n/a | |
| -$2.1M | -4.1x | 0.0x | |
| -$18.4M | -0.2x | 0.1x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Regenerative Medicine